Article title: Nrf2 expression in pancreatic stellate cells promotes progression of cancer Authors: Yu Tanaka, Shin Hamada, Ryotaro Matsumoto, Keiko Taguchi, Masayuki Yamamoto, Atsushi Masamune From the authors: “These results demonstrate that Nrf2 actively contributes to the function of [pancreatic…
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new method to measure breast cancer response, a new immunotherapy approach for multiple myeloma, characterization of the immune landscape of cholangiocarcinoma, a new contrast agent to improve molecular imaging techniques, and new treatment targets in breast, gynecologic and pancreatic cancers.
A large international collaboration led by researchers from the Johns Hopkins Kimmel Cancer Center has identified promising new targets for pancreatic cancer treatment and early diagnosis after examining various aspects of these tumors’ genes and proteins.
A new study in Science finds that pancreatic cells display an adaptive response to repeated inflammation that initially protects against tissue damage but can promote tumor formation in the presence of mutant KRAS.
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified how restoring a missing molecule in pancreatic fibrosis could help deliver treatments to cancer cells.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts.
We spoke with hematology oncologist James Orsini, Jr., M.D., to learn more about pancreatic cancer
Current advances include insights into anti-tumor responses, a targeted therapy combination for biliary tract cancers, biomarkers that may predict response to DNA damage repair inhibitors, a “virtual biopsy” using artificial intelligence to characterize tumors, new targeted and immunotherapy approaches for pancreatic cancer, understanding the impact of TP53 mutations on acute myeloid leukemia treatments, as well as a new strategy to overcome treatment-resistant KRAS-mutant lung cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include expanded use of a targeted therapy for a new group of patients with leukemia, molecular studies yielding novel cancer therapeutic targets, insights into radiation therapy resistance and a community intervention to reduce cervical cancer rates.
An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy.
UNSW medical researchers have found a way to starve pancreatic cancer cells and ‘disable’ the cells that block treatment from working effectively.
Probing the unique biology of human pancreatic cancer cells in a laboratory has yielded unexpected insights of a weakness that can be used against the cells to kill them.
Led by Princess Margaret Cancer Centre Scientist Dr. Marianne Koritzinsky, researchers showed that about half of patient-derived pancreatic cancer cell lines are highly dependent or “addicted” to the protein peroxiredoxin 4 (PRDX4), as a result of the altered metabolic state of the cancer cell. This addiction, which is vital for the cancer cell’s survival, makes it a precise, potential target against the cancer.
Researchers have successfully created the first 3D organoid models of the pancreas from human stem cells. This first-of-its-kind organoid model includes both the acinar and ductal structures that play a critical role in the majority of pancreatic cancers.
Atlantic Health System Cancer Care physicians are co-authors of five original studies presented at this year’s AACR Annual Meeting, held virtually April 10-15 and May 17-21. The AACR meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers.
MD Anderson and TriSalus announced a strategic research collaboration to evaluate the treatment of liver and pancreas tumors with the investigational therapy SD-101 in combination with immunotherapy using a novel delivery approach.
Patients with stage II pancreatic cancer who are treated with chemotherapy followed by resection (an operation that removes the cancerous part of the organ, structure or tissue) live nearly twice as long as patients who receive only chemotherapy.
A team of researchers from the UCLA Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health to identify new ways to treat pancreatic cancer.
A collaborative study by Stony Brook University scientists, published in Nature Communications, takes an initial step toward better understanding how KRAS drives immune evasion and demonstrates a lowering of the KRAS activity resulting in a more favorable immune environment to fight cancer.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center demonstrated that a new tumor-penetrating therapy could enhance the effects of chemotherapy, reduce the spread of pancreatic cancer and increase survival in animal models.
Contrary to long-held beliefs, new research finds that collagen in the tumor microenvironment may not promote cancer development but plays a protective role in controlling pancreatic cancer growth. The new findings could have important therapeutic implications.
UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling (IFN).
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won’t respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight.
Researchers at Rush University Medical Center have found that opioid use might increase a person’s risk of developing pancreatic cancer.
Henry Ford Health System today announced a $16 million gift to its Henry Ford Pancreatic Cancer Center (HFPCC), which was launched in 2018 by an initial $20 million gift from the same donor, who wishes to remain anonymous. The gift will bolster the HFPCC’s clinical and translational research endeavors in the fight against this devastating disease, for which the five-year survival rate is only 9 percent.
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators.
Longtime “Jeopardy!” host Alex Trebek announced it to the world on March 6, 2019: Like 50,000 other Americans each year, he had been diagnosed with stage 4 pancreatic cancer.
Rutgers Cancer Institute of New Jersey expert addresses what you should know about pancreatic cancer including risks, symptoms and treatment.
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
Pancreatic cancer often is hidden and doesn’t cause symptoms until it has spread. It is a leading cause of cancer deaths in the world.
November 19 is World Pancreatic Cancer Day, but the entire month of November is meant to bring awareness to this disease.
Advances in screening and early detection for high-risk people, minimally invasive surgical innovations and new genetic classifications are changing the outlook for pancreatic cancer, says Dr. Michael Wallace, a Mayo Clinic gastroenterologist.
With the recent passing of Jeopardy host Alex Trebek, Rutgers Cancer Institute of New Jersey expert explains pancreatic cancer and the progress being made with this disease through research and clinical trials.
In mourning of the death of Alex Trebek,Timothy Donahue, MD, chief of surgical oncology at UCLA’s Jonsson Comprehensive Cancer Center is available to discuss complications from metastatic cancer of the pancreas and the advances in treatment for pancreatic cancer. More…
Emily LaVoy, PhD, of the University of Houston, and colleagues explored the effects of moderate-intensity exercise on a mouse model of pancreatic cancer. Pancreatic cancer can be a particularly dangerous form of cancer because it is often diagnosed in later stages and spreads quickly. Though the trial sample was small—thus warranting further study—the results were optimistic.
Pancreatic cancer cells avert starvation by signaling to nerves, which grow into dense tumors and secrete nutrients.
A new analysis highlights the diversity of immune response in pancreatic cancer, and points toward the need for treatments tailored to individual patients.
GRAND RAPIDS, Mich. (Oct. 22, 2020) — Scientists have developed a simple, experimental blood test that distinguishes pancreatic cancers that respond to treatment from those that do not. This critical distinction could one day guide therapeutic decisions and spare patients with resistant cancers from undergoing unnecessary treatments with challenging side effects.
Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader has joined Mount Sinai Health System as Director of the Gastrointestinal (GI) Oncology Program and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.
Changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of cancer in preclinical models
In mourning of the death of Supreme Court Justice Ruth Badger Ginsburg,Timothy Donahue, MD, chief of surgical oncology at UCLA’s Jonsson Comprehensive Cancer Center is available to discuss complications from metastatic cancer of the pancreas and the advances in treatment…
Bart Rose, M.D. Department of Surgery Areas of expertise: Pancreatic cancer Diseases of the stomach Rose is director of the UAB Pancreatobiliary Disease Center — the first multidisciplinary program in the Alabama to treat diseases of the pancreas and bile…
Tweaking the adenovirus spike protein induces a more robust immune reaction for a cancer vaccine against gastric, pancreatic, esophageal and colon malignancies in animal models.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have uncovered a novel drug target, a protein called PPP1R1B, that stops the deadly spread of pancreatic cancer, called metastasis, when inhibited in mice. Published in Gastroenterology, the findings are a first step toward a potential treatment for one of the deadliest cancers known today.
UC Davis Health expert available to discuss pancreatic cancer: Why it is so lethal, and why there is hope The passing of Congressman John Lewis and recent update from Jeopardy host Alex Trebek renew focus on this rare but…
Rather than attacking cancer cells directly, new cell-model research probes weaknesses in pancreatic cancer’s interactions with other cells to obtain nutrients needed for tumor growth.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that pancreatic cancer metastasis—when tumor cells gain the deadly ability to migrate to new parts of the body—can be suppressed by inhibiting a protein called Slug that regulates cell movement. The study, published in the Journal of Experimental Medicine, also revealed two druggable targets that interact with Slug and hold promise as treatments that may stop the spread of pancreatic cancer.
Researchers at the University of Nebraska Medical Center have identified a key cell signaling pathway that drives the devastating muscle loss, or cachexia, suffered by many cancer patients. The study, which will be published May 22 in the Journal of Experimental Medicine, suggests that targeting this pathway with a drug already in phase 2 clinical trials for diabetes could prevent this syndrome.
A team of researchers from the UCLA Jonsson Comprehensive Cancer Center and peer institutions has been awarded a $5.75 million grant from the National Cancer Institute to study the correlation between obesity, inflammation and pancreatic cancer. The scientists hope their findings may help people avoid getting this cancer.
NCCN and the NCCN Foundation announce five new recipients for the 10th annual NCCN Foundation Young Investigator Awards (YIA) Program, overseen by the NCCN Oncology Research Program (ORP)
A possible new strategy for treating pancreatic cancer highlights the promise of collaboration between experts in both precision medicine and immunology. The findings from a team led by Agnieszka Witkiewicz, MD, and Erik Knudsen, PhD, at Roswell Park Comprehensive Cancer Center and published today in the journal Gut suggest a combination treatment approach that can make some breakthrough immunotherapy drugs effective for more patients with pancreatic cancer.
Polly’s Run is on a mission to end pancreatic cancer. The annual fundraiser is held each year in honor of Polly Rogers, whose best friends and three sons started the 5K run-walk event after she died in 2009. This year, the event will be held virtually.